NCT02220920View on ClinicalTrials.gov

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Canagliflozin (TA-7284)

The patients will receive Canagliflozin orally for 16 weeks

DRUG

Placebo

The patients will receive Placebo orally for 16 weeks

DRUG

Insulin

Trial Locations (7)

Unknown

Reserch site, Chugoku

Reserch site, Chūbu

Reserch site, Hokkaido

Reserch site, Kanto

Reserch site, Kinki

Reserch site, Kyushu

Reserch site, Tōhoku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY